These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 21971424)

  • 1. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.
    Basha G; Novobrantseva TI; Rosin N; Tam YY; Hafez IM; Wong MK; Sugo T; Ruda VM; Qin J; Klebanov B; Ciufolini M; Akinc A; Tam YK; Hope MJ; Cullis PR
    Mol Ther; 2011 Dec; 19(12):2186-200. PubMed ID: 21971424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA.
    Lin PJ; Tam YY; Hafez I; Sandhu A; Chen S; Ciufolini MA; Nabi IR; Cullis PR
    Nanomedicine; 2013 Feb; 9(2):233-46. PubMed ID: 22698807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.
    Xu Y; Ou M; Keough E; Roberts J; Koeplinger K; Lyman M; Fauty S; Carlini E; Stern M; Zhang R; Yeh S; Mahan E; Wang Y; Slaughter D; Gindy M; Raab C; Thompson C; Hochman J
    Mol Pharm; 2014 May; 11(5):1424-34. PubMed ID: 24588618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA.
    Chen S; Tam YYC; Lin PJC; Sung MMH; Tam YK; Cullis PR
    J Control Release; 2016 Aug; 235():236-244. PubMed ID: 27238441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of PEGylation on biodistribution and gene silencing of siRNA/lipid nanoparticle complexes.
    Bao Y; Jin Y; Chivukula P; Zhang J; Liu Y; Liu J; Clamme JP; Mahato RI; Ng D; Ying W; Wang Y; Yu L
    Pharm Res; 2013 Feb; 30(2):342-51. PubMed ID: 22983644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.
    Chen S; Tam YY; Lin PJ; Leung AK; Tam YK; Cullis PR
    J Control Release; 2014 Dec; 196():106-12. PubMed ID: 25285610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of DLin-MC3-DMA and ALC-0315 for siRNA Delivery to Hepatocytes and Hepatic Stellate Cells.
    Ferraresso F; Strilchuk AW; Juang LJ; Poole LG; Luyendyk JP; Kastrup CJ
    Mol Pharm; 2022 Jul; 19(7):2175-2182. PubMed ID: 35642083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
    Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
    Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.
    Jyotsana N; Sharma A; Chaturvedi A; Budida R; Scherr M; Kuchenbauer F; Lindner R; Noyan F; Sühs KW; Stangel M; Grote-Koska D; Brand K; Vornlocher HP; Eder M; Thol F; Ganser A; Humphries RK; Ramsay E; Cullis P; Heuser M
    Ann Hematol; 2019 Aug; 98(8):1905-1918. PubMed ID: 31104089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.
    Sato Y; Hashiba K; Sasaki K; Maeki M; Tokeshi M; Harashima H
    J Control Release; 2019 Feb; 295():140-152. PubMed ID: 30610950
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Algarni A; Pilkington EH; Suys EJA; Al-Wassiti H; Pouton CW; Truong NP
    Biomater Sci; 2022 May; 10(11):2940-2952. PubMed ID: 35475455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.
    Hashiba K; Sato Y; Harashima H
    J Control Release; 2017 Sep; 262():239-246. PubMed ID: 28774839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo.
    Lee JB; Zhang K; Tam YY; Tam YK; Belliveau NM; Sung VY; Lin PJ; LeBlanc E; Ciufolini MA; Rennie PS; Cullis PR
    Int J Cancer; 2012 Sep; 131(5):E781-90. PubMed ID: 22095615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver.
    Tao W; Davide JP; Cai M; Zhang GJ; South VJ; Matter A; Ng B; Zhang Y; Sepp-Lorenzino L
    Mol Ther; 2010 Sep; 18(9):1657-66. PubMed ID: 20628357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus.
    Sato Y; Matsui H; Yamamoto N; Sato R; Munakata T; Kohara M; Harashima H
    J Control Release; 2017 Nov; 266():216-225. PubMed ID: 28986168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA.
    Tam YY; Chen S; Zaifman J; Tam YK; Lin PJ; Ansell S; Roberge M; Ciufolini MA; Cullis PR
    Nanomedicine; 2013 Jul; 9(5):665-74. PubMed ID: 23219877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.
    Jayaraman M; Ansell SM; Mui BL; Tam YK; Chen J; Du X; Butler D; Eltepu L; Matsuda S; Narayanannair JK; Rajeev KG; Hafez IM; Akinc A; Maier MA; Tracy MA; Cullis PR; Madden TD; Manoharan M; Hope MJ
    Angew Chem Int Ed Engl; 2012 Aug; 51(34):8529-33. PubMed ID: 22782619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid nanoparticles for short interfering RNA delivery.
    Leung AK; Tam YY; Cullis PR
    Adv Genet; 2014; 88():71-110. PubMed ID: 25409604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery.
    Zimmermann CM; Baldassi D; Chan K; Adams NBP; Neumann A; Porras-Gonzalez DL; Wei X; Kneidinger N; Stoleriu MG; Burgstaller G; Witzigmann D; Luciani P; Merkel OM
    J Control Release; 2022 Nov; 351():137-150. PubMed ID: 36126785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced Delivery of siRNA to Retinal Ganglion Cells by Intravitreal Lipid Nanoparticles of Positive Charge.
    Huang X; Chau Y
    Mol Pharm; 2021 Jan; 18(1):377-385. PubMed ID: 33295773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.